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Abstract:  
Gender differences exist in clinical outcomes following routine PCI, but studies reporting such outcomes following 
CTO PCI are limited. We assessed the characteristics and outcomes of female patients undergoing chronic total 
occlusion (CTO) percutaneous coronary intervention (PCI).We retrospectively analysed a dedicated national 
(United Kingdom) prospective CTO database from 2011-2015 for outcomes and characteristics of female patients 
undergoing CTO PCI (unmatched and propensity matched). Female patients constituted 20.5% (n=260/1271) of the 
un-matched cohort and 33.3% (n=233/699) of the matched cohort and were more likely to be older (> 70 years of 
age females, 48% in the unmatched and 45% in the matched cohort).  An increased in-hospital complication rate 
was observed in female patients (unmatched: 10% females versus 4.45% males, p=0.0012 and matched 9.87% 
females versus 3.86% males, p=0.0032). Coronary perforation, bleeding and contrast induced nephropathy (CIN) 
were more frequently observed in female patients. Femoral access site with > 6 French sheath was associated with 
an increased risk of bleeding. Presence of calcification in the CTO artery was associated with coronary perforation 
(grade III) in female patients in the matched cohort (p=0.007). Female patients undergoing CTO PCI were older 
and experienced increased of in-hospital complications. Increased awareness of these complications could 
influence the selection of access site and sheath size, the need for pre-hydration, judicious choice of balloon size, 
collateral selection and wire placement in female patients undergoing CTO PCI. 
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Introduction: 
 Chronic Total Occlusion (CTO) Percutaneous Intervention (PCI) has generated increasing interest with the 
availability of new techniques and tools resulting in improved success rates, despite an increase in the complexity 
of arteries treated 
1
. However, data regarding gender differences in CTO PCI are limited. Female patients are 
under-represented in published CTO PCI literature with the proportion of female patients varying from 14% to 
21% 
2-5
.  Although similar procedural success rates are seen in both men and women undergoing CTO PCI, a 
greater reduction in mortality has been reported in the male cohort 
3
, potentially suggesting an unequal benefit of 
CTO PCI in male patients. It is well documented that gender differences exist in clinical outcomes following 
routine PCI 
6-8
, but studies reporting such outcomes following CTO PCI are very limited. We aimed therefore to 
assess the characteristics and complications (in-hospital and 30-day outcomes) of female patients, when compared 
to their male counterparts undergoing CTO PCI.  
Methods: 
 Dedicated, expert CTO PCI operators (lifetime experience of >300 cases per operator) from the United 
Kingdom prospectively enter baseline, procedural and outcome details into an anonymised online audit tool for 
consecutive CTO PCI cases. Participation is entirely voluntary and non/pre proctored CTO operators do not 
contribute to this database. We retrospectively analysed this database for outcomes and characteristics of patients 
undergoing CTO PCI from June 2011 to February 2015. Patients who had more than one CTO treated by PCI were 
entered as separate procedures. For patients who required more than one PCI attempt for the same CTO, only the 
final procedure was included. Demographics, procedural variables, procedural complications and success rates 
(including success for the first CTO PCI attempt) were compared between male and female patients. CTOs were 
defined as lesions with angiographic evidence of a total occlusion with thrombolysis in myocardial infarction 
(TIMI) 0 grade flow and estimated occlusion duration of >3 months
1
. Procedural success was defined as restoration 
of antegrade TIMI 3 flow with <30% residual stenosis within the treated segment
1
. Definitions of other procedural 
characteristics are as described in detail by Wilson et al
1
.   
In-hospital complications evaluated included were a composite of coronary perforation (Ellis grade III), 
acute vessel closure, bleeding (according to site- local haematoma, retroperitoneal or gastrointestinal), peri-
procedural myocardial infarction (MI: chest pain +/- ECG changes with typical rise and fall of cardiac biomarkers), 
transient ischaemic attack (TIA)/stroke, contrast induced nephropathy (CIN: acute kidney injury leading to dialysis 
or leading to an increase in serum Creatinine >25% from baseline) and death. Follow-up complications included 
composite of stent thrombosis, TIA/stroke, MI at 30 days and death.  
4 
 
SPSS version 20 was used for statistical analysis (IBM Corporation, Armonk, NY, USA). Missing variables 
were replaced by mean of nearest neighbour. Variables with >10% missing data were excluded. Categorical 
variables were presented as percentage and continuous variables as mean (± standard deviation). Differences in 
categorical variables were tested by the chi-square or Fisher’s exact test and differences in continuous variables by 
the student’s t test or Mann Whitney U test. Variables were tested for normality and non–normal continuous 
variables were log transformed for inclusion in the analysis. To overcome the limitations of the observational 
nature of our study, we performed a propensity score matched analysis and compared variables between males and 
females in both the unmatched and matched patient cohort. The propensity score was derived by regression 
analysis with gender as the dependent variable and the following variables included: age, chronic kidney disease 
(CKD), history of smoking, hypertension (HTN), diabetes mellitus (DM), history of stroke, previous history of 
coronary artery bypass graft (CABG) surgery, history of previous PCI, hypercholesterolemia, peripheral vascular 
disease (PVD) and family history of coronary artery disease (CAD). 
Propensity score matching was performed (2:1 nearest neighbour) without replacement and with calipers 
(set at 0.2 of the standard deviation of the logit of the propensity score) 
9
. We ensured balance in the propensity 
score of the matched samples by assessing the standardised difference in the mean propensity score (0.36) , the 
ratio of the variance of the score (1.22) in the two groups 
10
 and in addition single factor ANOVA demonstrated a 
Levene statistic p>0.05  indicative of no difference in the two groups. Demographics, procedural variables, 
procedural complications and success rates (including success for the first CTO PCI attempt) were compared again 
between male and female patients in this matched cohort.  
Results:  
Female patients constituted 20.5% (n=260) of the un-matched cohort of a total of 1271 and were 
significantly older, with almost half of the female population older than 70 years of age (table 1). Female patients 
were less likely to be smokers (current or ex) or have undergone CABG in the past (table 1) in the unmatched 
cohort. Lesion complexity, as defined by the JCTO score, was similar between the two groups (table 2). Final CTO 
PCI approach was similar between the groups, except for Retrograde Dissection Re-entry (RDR), which was more 
common in male patients (p=0.04, table 2). Fluoroscopy dose, procedural time, screening time and contrast load 
were all significantly lower in female patients. Success rates were no different, even taking into consideration first 
attempt at CTO PCI (table 2).  
 In-hospital complications were more common in females (females 10.0% versus males 4.45%, p=0.0012). 
Coronary perforation (Ellis III), bleeding complications and CIN were more frequent in female patients (table 3). 
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Both male and female patients in the unmatched cohort with coronary perforation were more likely to have 
calcification and tortuosity of the CTO artery (p<0.01 for all). 
Propensity score matching was performed (2:1 nearest neighbour) without replacement and with calipers 
resulted in a cohort of 466 male patients matched to 233 females (2:1 matching) from the original database 
9
. The 
matched group was assessed for differences in baseline, procedural characteristics and outcomes (table 4).  
The 233 propensity score matched females demonstrated similar baseline characteristics as the unmatched 
female cohort (table 4). Female patients were older and less likely to be smokers or undergone previous CABG 
(table 4). Those >70 years constituted nearly half of the matched female population (45.1%, 105/233). Lesion 
complexity continued to be similar between female and male patients in the matched group (table 5). 
Final CTO PCI approach was less likely to be RDR in women compared to men undergoing CTO PCI. 
Fluoroscopy dose and total contrast use were again significantly less in female patients. Success rates were similar 
(males 82.6% versus females 85%, p=ns) and continued to be >80% as in the unmatched cohort (table 5). 
Significantly increased in-hospital complications (females 9.87% versus males 3.86%, p=0.0032) i.e. coronary 
perforation (Ellis III), bleeding complications and CIN were more frequent in female patients (table 6).  A 
significant association was only seen in female patients between coronary perforation and presence of calcification 
in the CTO artery (p=0.007).  
Female patients in both the unmatched and matched cohorts with femoral access site sheath size > 6 French 
were more likely to have peripheral bleeds. Retroperitoneal bleeds were significantly more common in female 
patients in both the unmatched (1.9% females versus 0.5% males, p=0.035, table 3) and the matched cohort (2.1% 
females versus 0.4% males, p=0.04, table 6). 
Neither in-hospital nor 30-day mortality occurred in the female cohort. Follow up outcomes at 30 days 
occurred in <2% of female patients (tables 3 and 6).  
Discussion: 
In this observational, propensity matched analysis of a prospective CTO PCI database, we have identified 
that women compared to men, present at an older age for CTO PCI and are less likely to have undergone previous 
CABG. Procedural time, fluoroscopy dose, screening time and contrast load were all significantly lower in female 
patients. Success rates were no different, even taking into consideration first attempt at CTO PCI (table 2).  In-
hospital complications were more common in females versus males in both the unmatched (females 10.0% versus 
males 4.45%, p=0.0012) and matched cohort (females 9.87% versus males 3.86%, p=0.0032). Specifically, 
coronary perforation (Ellis III), bleeding complications and CIN were more frequent in female patients (table 3). 
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The average age of women at presentation was greater compared to men (68.5 ± 9.8 vs. 64.2±10.3 
p<0.0001). It may reflect the fact that women are in part protected from ischaemic heart disease pre-menopause so 
the disease process may simply be delayed. It is well recognised that women compared to men, may present later in 
the disease process or have treatment deferred due to gender bias
11,12
. Despite females making up 30-40% of 
angiographic coronary artery disease studies only 20% of our database population are female. In a large registry of 
patients undergoing diagnostic coronary angiography a CTO was identified in 18.4% of all cases (post CABG 
patients were excluded)
4
 - females again made up only 20% of this group.  
We know that despite a similar disease burden, women are more likely to be treated medically and less 
likely to be referred for CABG than male counterparts 
4,13
. Placing a graft on an artery with a flow limiting stenosis 
will result in the lesion progressing to complete obstruction in up to 50% of cases in a 1 year period 
14
. The 
Canadian registry identified a CTO in 54% of patients post CABG (compared with 18.4% without prior CABG) 
4
. 
The fact that females are less likely to be referred for CABG may impact favourably on CTO formation. Our data 
supports this with 13.8 % of women having previous CABG versus 24.1% of males (table 1). There may well also 
be a referral bias against females with symptomatic CTO’s.  
While there are similar J-CTO scores between the groups there is a suggestion that the female cases were in 
fact less complex (tables 2 and 5). In the female patients there were lower fluoroscopy doses, procedure times, 
screening times and contrast doses with similar success rates compared to male patients. These indirectly suggest 
reduced complexity in this group. 
Despite possible less complex anatomy the procedural complication rates were much higher in the female 
group. In hospital event rates occurred in 9.87% of females versus 3.86 % of matched males (Table 6). Over half of 
all events were bleeding related and in particular when the femoral sheath size was >6French (6.3% vs 2.1%, 
p=0.015). A previous CathPCI registry analysis has demonstrated that female patients have double the risk of 
bleeding complications 
15
. The use of larger size femoral access sheaths was associated with an increased risk of 
bleeding. Female patients are known to have smaller diameter femoral arteries compared to males 
16
 and female 
gender is a known predictor of retroperitoneal bleeds 
17
. Utilising the radial artery for at least one of the access sites 
or performing femoral access under ultrasound guidance 
18
may help in reducing this complication. While all the 
operators use fluoroscopy to locate the femoral head and guide the femoral puncture using additional imaging 
modalities including ultrasound guidance to maximise the chance of a clean femoral puncture may have merit in 
this group
19
.   
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The rates of grade 3 coronary perforations were higher in the unmatched (3.08% versus 0.5%, p=0.001) and 
matched female group compared to male patients (3.0 % versus 1.07%, p=ns) (tables 3 and 6). In routine PCI, 
known risk factors predisposing to coronary perforation include female gender, older age, treated hypertension and 
calcified arteries 
20-25
. It appears that this increased risk of coronary perforation also occurs in females during CTO 
PCI. Intra-vascular Ultrasound (IVUS) studies have demonstrated that female coronary arteries are smaller even 
after adjusting for body surface area
26
. This may in part explain the higher perforation rates.  We also established a 
correlation between the presence of calcification in the CTO artery and perforation. The final strategy was less 
commonly RDR in the female compared to the male group (both unmatched and matched cohorts, tables 2 and 5). 
We hypothesis that collateral channels in females may be more challenging to cross than in males due to smaller 
size, tortuosity and angulation, resulting in fewer RDR procedures. 
Published registry data has demonstrated the incidence of CIN peri-PCI to be as high as 3.3% 
27
. Despite 
use of reduced contrast load in female patients, the incidence of CIN in females was significantly greater than in 
their male counterparts in both the unmatched (females 1.2% versus males 0.2%, p=0.005) and matched cohorts 
(females 2.1% versus males 0.2%, p=0.017) (tables 3 and 6). CIN was significantly more frequent in female 
patients who underwent >1 CTO PCI procedure compared to male patients. None of the male patients who 
underwent > 1 CTO PCI procedure developed CIN. Older age, pre-existing renal failure and diabetes mellitus are 
known to be contributory to CIN 
28
, but female gender has not been shown to be a predictor of CIN post PCI. Most 
of the female patients (4 out of 5) who developed CIN were older than 70 years of age. A combination of older age 
and repeat procedures in female patients could have contributed to the higher incidence of CIN. As increased age 
>75 years is a risk factor for CIN 
29
, this may be a subset of patients who would benefit from more aggressive 
management of medications and hydration peri-procedure, especially if the first CTO PCI is a failure and further 
attempts are planned. 
 This study has a number of potential limitations. Participation in this registry is entirely voluntary but the 
contributing operators are all dedicated/proctored operators. While this might contribute to some bias, it is difficult 
to quantify because proctored operators are known to attempt CTOs with a higher J-CTO score (≥2) and 
demonstrate higher success rates with similar complication rates compared to non/pre-proctored operators 
30
. 
Despite propensity matching, ours is an observational study. We have relied on the individual PCI centres to enter 
clinical data including complications into the database and there is the potential for under reporting. Some of the 
definitions of complications are operator dependent (e.g. bleeding) and validation of the complications is 
dependent on the clinical data input. In addition, data regarding details of dual antiplatelet therapy, dose of Heparin 
8 
 
or concurrent anticoagulation was not available. This could potentially create bias and influence bleeding 
outcomes. The number of female patients included in our study although similar to other CTO PCI studies (14-21 
%), 
2-5
, still under-represents the female population. However, this is one of the first studies to evaluate 
characteristics and complications of female patients undergoing CTO PCI. 
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Table 1: Baseline characteristics of unmatched patients 
 
  
     TIA*: Transient Ischaemic Attack; CAD†: Coronary Artery Disease; PCI‡: Percutaneous Coronary Intervention  
 
Variable Men  
n=1011 
Women 
n=260 
Significance 
p value 
Age in years 
64.2±10.3 68.5±9.8 p<0.0001 
>70 years 
289 (28.6%) 125 (48.1%)  p<0.0001 
Hypertension 
684 (67.7%) 190 (73.1%) p=0.10 
Hypercholesterolemia 
690 (68.2%) 184 (70.8%) p=0.45 
Diabetes Mellitus 
250 (24.7%)  62 (23.8%) p=0.81 
Smoker  
696 (68.8%) 136 (52.3%) p=<0.0001 
Angina (CCS class >2) 
476 (47.1%) 142 (54.6%) p=0.03 
Previous TIA
*
/Stroke 
50 (4.9%) 11 (4.2%) p=0.75 
Previous Myocardial 
Infarction 559 (55.3%) 134 (51.4%) p=0.30 
Previous coronary bypass
 
244 (24.1%) 36 (13.8%) p<0.001 
Chronic Kidney Disease 
 
129 (12.8%)  38 (14.6%) p=0.41 
Family History of CAD
† 
337 (33.3%) 90 (34.6%) p=0.71 
Previous PCI
‡ 
566 (56.0%) 135 (51.9%) p=0.26 
Peripheral Vascular Disease 
 
107 (10.6%) 28 (10.8%) p=0.91 
Table 1
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Table 2: Procedural characteristics of unmatched patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    
 
                                       
                                   
                                   
 
                                    
                                   CTO*: Chronic Total Occlusion; RCA†: Right Coronary Artery; J-CTO‡: Japanese CTO score; PCI§: Percutaneous Coronary     
                                   Intervention; (cGy/m2)¶: CentiGrey per square meter 
 
 
 
Variable Men 
n=1011 
Women 
n=260 
Significance 
p value 
CTO* coronary artery RCA† 516 (51.0%) 155 (59.6%)  p=0.01 
Access site femoral 859 (85.0%)  226 (86.9%) p=0.49 
Femoral access site >6French 779 (77.1%) 202 (77.7%) p=0.87 
J-CTO‡  score ≥2 748 (74.0%) 188 (72.3%) p=0.58 
J-CTO‡  score 0 91 (9.0%) 20 (7.7%) - 
J-CTO‡  score 1 172 (17.0%) 52 (20%) - 
J-CTO‡  score 2 240 (23.7%) 67 (25.8%) - 
J-CTO‡  score 3 227 (22.5%) 64 (24.6%) - 
J-CTO‡  score 4 222 (22.0%) 44 (16.9%) - 
J-CTO‡  score 5 59 (5.8%) 13 (5.0%) - 
Single CTO PCI
§
 procedure  840 (83.1%) 232 (89.2%) p=0.016 
 
Primary CTO PCI
§
 approach 
 
   
Antegrade Wire  
Escalation 
670 (66.3%) 184 (70.8%) p=0.18 
Antegrade Dissection  
Re-entry 
95 (9.4%) 29 (11.2%) p=0.41 
Retrograde Wiring 119 (11.8%) 23 (8.8%) p=0.22 
Retrograde Dissection  
Re-entry 
127 (12.6%) 24 (9.2%) p=0.16 
 
Final CTO PCI
§
 approach 
 
   
Antegrade Wire Escalation 444 (43.9%) 127 (48.8%) p=0.16 
Antegrade Dissection  
Re-entry 
243 (24.0%) 59 (22.7%) p=0.68 
Retrograde Wiring 75 (7.5%) 26 (10%) p=0.71 
Retrograde Dissection  
Re-entry 
249 (24.6%) 48 (18.5%) p=0.04 
Fluoroscopy dose (cGy/m2 )
¶
 14712±9743.66 10170±8388.48 p<0.0001 
Procedure time 111±48.7 104±43.9 p=0.05 
Screening Time in minutes 43±23.8 38±19.8 p=0.02 
Contrast load in milliliters 
(ml) 
323±131.06 294±118.06 p=0.002 
Success -single CTO PCI 
procedure 
764/840 (91.0%) 209/232 (90.1%) p=0.70 
Success -all patients 833 (82.4%) 221 (85%) p=0.36 
Failure due to sub-intimal 
passage and inability to  
re-enter true lumen  
89/178 (50%) 23/39 (59.0%) p=0.38 
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Table 3: Details of Complications in unmatched cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 MI*: Myocardial Infarction; TIA†: Transient Ischemic Attack; CIN‡: Contrast Induced Nephropathy 
 
Variable Men 
n=1011 
Women 
n=260 
Significance 
p value 
In-hospital outcomes 
(composite) 45(4.45%) 26 (10.0%) p=0.001 
Coronary Perforation  
Ellis Grade III 5 (0.50%) 8 (3.08%) p=0.001 
Acute Vessel Closure 
5 (0.50%) 2 (0.80%) p=0.64 
Bleeding  25 (2.50%) 15 (5.80%) p=0.02 
-Retroperitoneal bleed 5 (0.5%) 5 (1.9%) p=0.04 
-Femoral access>6French 23 (3.0%) 14 (6.9%) p=0.01 
Peri-procedural MI* 9 (0.9%) 3 (1.2%) p=0.72 
TIA
†
/Stroke 3 (0.3%) 1 (0.4%) p=1.00 
CIN
‡ 
 (all patients) 2 (0.2%) 5 (1.9%) p=0.005 
CIN
‡
  (patients >1 CTO 
PCI procedure) 
0/171 (0%) 3/29 (10.3%) p=0.003 
Death 2 (0.2%) 0 (0%) p=1.00 
Follow-up outcomes  
(30 days composite) 14 (1.4%) 5 (1.9%) p=0.57 
Stent thrombosis 9 (0.9%) 1 (0.4%) p=0.70 
- Definite 7 0 - 
- Probable 1 0 - 
- Possible 1 1 - 
TIA
†
/Stroke 0 (0%) 1 (0.4%) p=0.20 
MI*  5 (0.5%) 3 (1.2%) p=0.21 
Death 0 (0%) 0 (0%) - 
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          Table 4: Baseline characteristics of matched patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         TIA*: Transient Ischaemic Attack; CAD†: Coronary Artery Disease; PCI‡: Percutaneous Coronary Intervention 
 
 
Variable Men 
n=466 
Women 
n=233 
Significance 
p value 
Age in years 66.0±10.1 68.±9.7 p=0.01 
>70 years 164 (35.2%)  105 (45.1%) p=0.01 
Hypertension 320 (68.7%) 170 (73.0%) p=0.26 
Hypercholesterolemia 320 (68.7%) 164 (70.4%) p=0.66 
Diabetes Mellitus 132 (28.3%) 58 (24.9%) p=0.37 
Smoker  305 (65.5%) 129 (55.4%) p=0.01 
Angina (CCS class >2) 226 (48.5%) 128 (54.9%) p=0.13 
Previous TIA
*
/Stroke 31 (6.7%) 11 (4.7%) p=0.40 
Previous Myocardial Infarction 262 (56.2%) 122 (52.4%) p= 0.33 
Previous coronary bypass
 93 (20.0%) 34 (14.6%) p=0.10 
Chronic Kidney Disease 
 61 (13.1%) 37 (15.9%) p=0.36 
Family History of CAD
† 148 (31.8%) 84 (36.1%) p=0.27 
History of previous PCI
‡ 263 (56.4%) 122 (52.4%) p=0.33 
Peripheral Vascular Disease 
 59 (12.7%) 27 (11.6%) p=0.72 
Table 4
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Table 5: Procedural characteristics of matched patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
  
 
 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
  
                                     
                                              
 
 
                                              
                                             
                                             
                                               
                                              CTO*: Chronic Total    Occlusion; RCA†: Right Coronary Artery; J-CTO‡: Japanese CTO score; PCI§: Percutaneous                                                    
                                              Coronary Intervention; (cGy/m2)¶: CentiGrey per square meter 
  
Variable Male patients 
n=466 
Female Patients 
n=233 
Significance 
p value 
CTO* coronary artery RCA† 245 (52.6%) 140 (60.1%) p=0.06 
Access site femoral 387 (83.0%) 202 (86.7%) p=0.23 
Femoral access site >6French 379 (81.3%) 191 (82.0%) p=0.92 
J-CTO‡  score ≥2 354 (76.0%) 169 (72.5%) p=0.36 
J-CTO‡  score 0 41 (8.8%) 18 (7.7%) - 
J-CTO‡  score 1 71 (15.2%) 46 (19.7%) - 
J-CTO‡  score 2 127 (27.3%) 61 (26.2%) - 
J-CTO‡  score 3 97 (20.8%) 55 (23.6%) - 
J-CTO‡  score 4 107 (23.0%) 40 (17.2%) - 
J-CTO‡  score 5 23 (4.9%) 13 (5.6%) - 
Single CTO PCI
§
 procedure  379 (81.33%) 205 (88.0%) p=0.03 
 
Primary CTO PCI
§
 approach 
 
   
Antegrade Wire  
Escalation 
306 (65.7%)  163 (70.0%) p=0.27 
Antegrade Dissection  
Re-entry 
45 (9.7%) 27 (11.6%) p=0.43 
Retrograde Wiring 58 (12.4%) 21 (9.0%) p=0.21 
Retrograde Dissection  
Re-entry 
57 (12.2%) 22 (9.4%) p=0.31 
 
Final CTO PCI
§
 approach 
 
   
Antegrade Wire Escalation 214 (45.9%) 110 (47.2%)  p=0.75 
Antegrade Dissection  
Re-entry 
112 (24.0%) 55 (23.6%) p=0.93 
Retrograde Wiring 34 (7.3%) 23 (9.9%) p=0.24 
Retrograde Dissection  
Re-entry 
106 (22.7%) 45 (19.3%) p=0.33 
Fluoroscopy dose (cGy/m2 )
¶
 14205±9764.22 10434±8617.52 p<0.0001 
Procedure time 109±47.2 105±44.5 p=0.50 
Screening Time in minutes 41±22.6 39±20.2 p=0.22 
Contrast load in milliliters 
(ml) 
322±133.7 298±121.7 p=0.06 
Success rate in single CTO 
PCI procedure 
341/379 (89.9%) 182/205 (88.8%) p=0.23 
Success rate in all patients 385 (82.6%) 198 (85%) p=0.45 
Failure due to sub-intimal 
passage and inability to  
re-enter true lumen 
44/81 (54.3%) 22/35 (62.9%) p=0.42 
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Table 6: Details of complications in matched cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                MI*: Myocardial Infarction; TIA†: Transient Ischemic Attack; CIN‡: Contrast Induced Nephropathy 
Variable Male patients 
n=466 
Female Patients 
n=233 
Significance 
p value 
In-hospital outcomes 
(composite) 
18 (3.86%) 23 (9.87%) p=0.003 
Coronary Perforation  
Ellis Grade III 
5 (1.07%) 7 (3.0%) p=0.12 
Acute Vessel Closure 2 (0.4%) 2 (0.9%) p=0.60 
Bleeding 8 (1.7%) 13 (5.6%) p=0.008 
-Retroperitoneal bleed 2 (0.4%) 5 (2.1%) p=0.04 
-Femoral access>6French 8 (2.1%) 12 (6.3%)  p=0.015 
Peri-procedural MI* 3 (0.6%) 3 (1.3%) p=0.41 
TIA
†
/Stroke 2 (0.4%) 1 (0.4%) p=1.00 
CIN
‡ 
(all patients) 1 (0.2%) 5 (2.1%) p=0.017 
CIN
‡ 
(patients >1 CTO 
PCI procedure) 
0/86 (0%) 3/28 (10.7%) p=0.014 
Death 1 (0.2%) 0 (0%) p=1.00 
Follow-up outcomes  
(30 days composite) 7 (1.5%) 4 (1.7%) p=1.00 
Stent thrombosis 4 (0.9%) 0 (0%) p=0.31 
- Definite 2 0 - 
- Probable 1 0 - 
- Possible 1 0 - 
TIA
†
/Stroke 0 (0%) 1 (0.4%) p=0.33 
MI*  3 (0.6%) 3 (1.3%) p=0.41 
Death 0 (0%) 0(0%) p=1.00 
Table 6
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